Author:
Zwicker Paula,Freitag Marcus,Heidel Florian H.,Kocher Thomas,Kramer Axel
Abstract
Abstract
Objectives
Oral mucositis caused by intensive cancer chemotherapy or radiotherapy frequently results in pronounced damage of the oral mucosa leading to painful oral hygiene. To support oral care, antimicrobial effective mouth rinses may be used. Thus, the efficacy of a hypochlorite-based mouth rinse (Granudacyn®), assumed to be highly biocompatible because of the compounds being part of the natural pathogen defense, as possible antiseptic agent in case of oral mucositis was compared to that of an octenidine based antiseptic mouth rinse (Octenidol® md).
Materials and methods
The study was conducted as monocentric, controlled, randomized, blind cross over comparative study on 20 volunteers. As a proof of principle, we performed the study on orally healthy subjects and not cancer patients. The efficacy was determined as reduction of colony forming units (cfu) on buccal mucosa as well as in saliva. After mouth rinsing for 30 s, samples were taken after 1 min, 15 min, 30 and 60 min. The lg-reduction was calculated as difference between lg-values of cfu pre- and post-treatment.
Results
Both antiseptic mouth rinses induced a significant reduction of cfu on buccal mucosa and in saliva 1 min after mouth rinsing. The effect persisted up to 60 min. The octenidine based rinse was significantly superior to the hypochlorite-based rinse up to the last sample 60 min after rinsing. However, the known cytotoxicity of octenidine argues against its application.
Conclusion
Within the limits of this study, due to its antiseptic efficacy, the hypochlorite-based rinse Granudacyn® can be regarded appropriate to support the oral hygiene in patients with a sensitive oral mucosa during an aggressive cancer chemotherapy and radiation treatment in case of oral mucositis.
Funder
Universitätsmedizin Greifswald
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Leitlinienprogramm Onkologie D, Krebsgesellschaft D, Krebshilfe AQMF. S3-Leitlinien Supportive Therapie bei onkologischen PatientInnen:Langversion1.1; 2017.
2. Kawajiri J, Nagata K, Nakamura A, Fujieda A, Ino K, Nomura J, et al. Clinical utility of oral management in allogeneic hematopoietic stem cell transplantation recipients: microbiological evidence based on molecular analysis of oral bacteria. Support Care Cancer. 2022;30:757–64. https://doi.org/10.1007/s00520-021-06462-9.
3. Hong CHL, Gueiros LA, Fulton JS, Cheng KKF, Kandwal A, Galiti D, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27:3949–67. https://doi.org/10.1007/s00520-019-04848-4.
4. Buglione M, Cavagnini R, Di Rosario F, Maddalo M, Vassalli L, Grisanti S, et al. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (part 2). Literature review and consensus statement. Crit Rev Oncol Hematol. 2016;102:47–54. https://doi.org/10.1016/j.critrevonc.2016.03.012.
5. Schmoll H-J, Höffken K, Possinger K. Kompendium internistische Onkologie. 1st ed. Berlin: Springer; 1986.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Palyatif Bakım ve Ağız Sağlığı: Bibliyometrik Çalışma;Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi;2023-12-28